Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 13/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27827424 | 0.87 | NR3C2 (0.56) | NR3C2PKMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL163628 | 0.87 | NR3C2 (0.49) | NR3C2PKMRIOK2MEN1KMT2A | |
| SCHEMBL21847287 | 0.85 | L3MBTL1 (0.50) | NR3C2RIOK2 | |
| SCHEMBL30893838 | 0.85 | L3MBTL1 (0.50) | NR3C2RIOK2 | |
| SCHEMBL5913167 | 0.84 | NR3C2 (0.53) | NR3C2PKMRIOK2MEN1KMT2A | |
| SCHEMBL9934078 | 0.83 | NR3C2 (0.51) | NR3C2PKMRIOK2MEN1KMT2A | |
| SCHEMBL27083330 | 0.83 | LOXL2 (0.59) | NR3C2PKMLOXL2 | |
| SCHEMBL5913025 | 0.82 | NR3C2 (0.49) | NR3C2PKMRIOK2MEN1KMT2A | |
| SCHEMBL2562571 | 0.81 | NR3C2 (0.50) | NR3C2PKMRIOK2MEN1KMT2A | |
| SCHEMBL1979971 | 0.81 | NR3C2 (0.57) | NR3C2PKMRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740581-B1 | 2, 4, 6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20080015233-A1 | 2,4,6-Substituted Pyridyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2008-01-17 | — | — | US | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | SSTR1, SSTR3, NPY1R | NR3C2 104/4885PKM 2917/4885RIOK2 2869/4885 |
| US-20080015233-A1 | 2,4,6-Substituted Pyridyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN2 | NR3C2 3875/4885PKM 2803/4885RIOK2 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.